Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Noramco, Teewinot link for cannabinoids

by Michael McCoy
March 27, 2017 | A version of this story appeared in Volume 95, Issue 13

The active pharmaceutical ingredient (API) maker Noramco plans to push into the cannabinoid business with the use of biosynthesis technology from Teewinot Life Sciences. Noramco says it will create 10 to 15 cannabinoid reference standards with the Teewinot technology. It will also evaluate using the technology to commercially produce dronabinol (synthetic THC), known for its effectiveness in pain management and other therapeutic uses. Albany Molecular Research Inc., another API maker, licensed Teewinot’s technology to make cannabichromene last year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.